Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

This study looked at 4261 biopsies that were sent by 930 physicians to Myriad Genetic Laboratories for CCP analysis.

In the study, patients were classified into AUA risk categories (lower, intermediate, and high) based on several factors, including PSA and Gleason score.

It was found that based on the CCP score, 36.8% and 21.2% of patients had a less and more aggressive cancer, respectively, than expected based on clinicopathologic prediction. This, Crawford says, represents an added way of classifying patients into risk categories.

<<<

View more from the 2015 GU Cancer Symposium